Viridian Therapeutics, Inc./DE: basic earnings per share

What this measure means

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-01-01 to 2023-12-31. The SEC response was captured on 2026-09-20.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Reading these values

This selected numerical history matches Diluted earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

For Viridian Therapeutics, this review covers only the selected 2021–2023 observations in its 2023 annual filing. The filing excludes potential common shares as anti-dilutive in all those loss periods, so basic and diluted loss per share are equal. Full scale-zero share counts follow the statement’s share/per-share exception to the thousands heading. EPS uses net loss rather than comprehensive loss after investment-value changes. This historical review does not establish the accounting treatment of later filings. Read the source filing.

Selected filing history

Related financial histories

• Viridian Therapeutics, Inc./DE: total assets
• Viridian Therapeutics, Inc./DE: total liabilities
• Viridian Therapeutics, Inc./DE: stockholders equity
• Viridian Therapeutics, Inc./DE: cash and cash equivalents
• Viridian Therapeutics, Inc./DE: net income or loss
• Viridian Therapeutics, Inc./DE: operating cash flow
• Viridian Therapeutics, Inc./DE: capital expenditure payments
• Viridian Therapeutics, Inc./DE: revenue
• Viridian Therapeutics, Inc./DE: financing cash flow
• Viridian Therapeutics, Inc./DE: investing cash flow
• Viridian Therapeutics, Inc./DE: retained earnings or deficit
• Viridian Therapeutics, Inc./DE: basic weighted-average shares
• Viridian Therapeutics, Inc./DE: diluted weighted-average shares
• Viridian Therapeutics, Inc./DE: diluted earnings per share
• Viridian Therapeutics, Inc./DE: net property, plant and equipment
• Viridian Therapeutics, Inc./DE: share-based compensation expense
• Viridian Therapeutics, Inc./DE: operating income or loss
• Viridian Therapeutics, Inc./DE: current assets
• Viridian Therapeutics, Inc./DE: interest expense
• Viridian Therapeutics, Inc./DE: current liabilities
• Viridian Therapeutics, Inc./DE: current accounts payable
• Viridian Therapeutics, Inc./DE: net current accounts receivable
• Viridian Therapeutics, Inc./DE: operating expenses
• Viridian Therapeutics, Inc./DE: net inventory
• Viridian Therapeutics, Inc./DE: cost of revenue
• Viridian Therapeutics, Inc./DE: selling, general and administrative expense
• Viridian Therapeutics, Inc./DE: research and development expense

Inspect the source

Entity

Viridian Therapeutics, Inc./DE / CIK 0001590750

Captured

2026-09-20T09:24:00.388Z

SEC response SHA-256

907b594c863d597442ab1ef3a5d74359a9418f23c7e0bb102180e38d47e78bab

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001590750.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))